- Home
- CLLS vs ACTU Comparison
CLLS vs ACTU Comparison
Compare CLLS & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- ACTU
- Stock Information
- Founded
- CLLS 1999
- ACTU 2015
- Country
- CLLS France
- ACTU United States
- Employees
- CLLS N/A
- ACTU N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- ACTU
- Sector
- CLLS Health Care
- ACTU
- Exchange
- CLLS Nasdaq
- ACTU NYSE
- Market Cap
- CLLS 148.1M
- ACTU 154.3M
- IPO Year
- CLLS 2007
- ACTU 2024
- Fundamental
- Price
- CLLS $1.32
- ACTU $6.70
- Analyst Decision
- CLLS Buy
- ACTU Strong Buy
- Analyst Count
- CLLS 3
- ACTU 1
- Target Price
- CLLS $7.00
- ACTU $20.00
- AVG Volume (30 Days)
- CLLS 839.3K
- ACTU 35.6K
- Earning Date
- CLLS 03-13-2025
- ACTU 05-21-2025
- Dividend Yield
- CLLS N/A
- ACTU N/A
- EPS Growth
- CLLS N/A
- ACTU N/A
- EPS
- CLLS N/A
- ACTU N/A
- Revenue
- CLLS $49,217,000.00
- ACTU N/A
- Revenue This Year
- CLLS $1.26
- ACTU N/A
- Revenue Next Year
- CLLS N/A
- ACTU N/A
- P/E Ratio
- CLLS N/A
- ACTU N/A
- Revenue Growth
- CLLS 435.38
- ACTU N/A
- 52 Week Low
- CLLS $1.14
- ACTU $5.51
- 52 Week High
- CLLS $3.38
- ACTU $11.73
- Technical
- Relative Strength Index (RSI)
- CLLS 49.18
- ACTU N/A
- Support Level
- CLLS $1.16
- ACTU N/A
- Resistance Level
- CLLS $1.35
- ACTU N/A
- Average True Range (ATR)
- CLLS 0.07
- ACTU 0.00
- MACD
- CLLS 0.01
- ACTU 0.00
- Stochastic Oscillator
- CLLS 69.23
- ACTU 0.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.